Notably, a search of a public BC dataset with Delta-HER2 signature genes showed that their specific enrichment correlated with ER-negative status, high tumor grade, and poor distant metastasis-free survival in metastatic BC patients [38]. This evidence concerns the gene ERBB2 and breast cancer.